Get the Daily Brief
Latest Biotech News
Mammoth prepares first trial — gene edit to lower triglycerides shows monkey data
Mammoth Biosciences disclosed preclinical nonhuman primate data for its lead in vivo gene‑editing program intended to permanently lower triglycerides and announced plans for a first clinical...
Pig‑to‑human auxiliary liver transplant — graft supported metabolism 38 days
Surgeons in China transplanted a genetically modified pig liver segment into a patient with cancer as an auxiliary graft; the xenograft supported metabolic function for 38 days before being...
Senate passes new Biosecure Act amendment — tighter US biotech ties to China loom
The U.S. Senate passed a revised version of the Biosecure Act as an amendment to the FY26 National Defense Authorization Act, seeking to restrict federal contracts and funding with biotechnology...
Illumina alliance tops 250K genomes — pharma partners ramp access to diverse cohorts
Illumina’s Alliance for Genomic Discovery has now sequenced over 250,000 genomes from the Vanderbilt BioVU biobank and added pharmaceutical partners including Alnylam, expanding industry access to...
Tempus wins $60.5M ARPA‑H contract — to power precision cancer ADAPT program
Tempus AI secured a $60.5 million, five‑year contract from ARPA‑H to provide sequencing, diagnostic assays and contract research services for the ADAPT precision cancer therapy initiative. The...
Epigenetic editor silences PCSK9 — durable LDL reductions seen in primates
Researchers reported that an mRNA‑delivered epigenetic editing therapy, dubbed Epi‑Reg, achieved long‑lasting reductions in PCSK9 expression and LDL cholesterol in human cells, mice and nonhuman...
Novo buys Akero for $4.7B — stakes claim in MASH drug class
Novo Nordisk agreed to acquire Akero Therapeutics for $4.7 billion in cash, securing efruxifermin, an FGF21 analogue in late‑stage testing for metabolic dysfunction‑associated steatohepatitis...
Bristol Myers spends $1.5B to join in vivo CAR‑T race
Bristol Myers Squibb agreed to acquire Orbital Therapeutics for $1.5 billion in cash, bringing Orbital’s in vivo CAR‑T technology into BMS’s cell‑therapy portfolio. The acquisition is the latest...
Senate advances Biosecure Act — federal biotech ties face new limits
The U.S. Senate passed a revised iteration of the Biosecure Act as an amendment to the National Defense Authorization Act, proposing restrictions on federal funding and contracting with...
Biopharma doubles down on in vivo CAR‑T: deals and awards pile up
Commercial and public funders are accelerating investment in in vivo CAR‑T approaches as early human data and enabling delivery technologies surface. Industry players have spent billions buying...
Epigenetic editing lowers LDL in primates — single dose durability
Researchers delivered an mRNA‑based epigenetic editor targeting PCSK9 that produced durable LDL cholesterol reductions in nonhuman primates for nearly a year after a single dose. The team reported...
Pan‑disease blood proteome: 9K samples map 59 illnesses — biomarker atlas
An international consortium led by KTH SciLifeLab and collaborators published a pan‑disease blood proteome that profiles protein changes across 59 diseases using Olink’s high‑throughput panels and...
Judge invalidates Scale patent — Parse Bio scores legal win
A U.S. district court found key claims of a Scale Biosciences patent invalid for inadequate written description and enablement, handing Parse Biosciences a win in an ongoing infringement dispute....
Evommune files for IPO — raise to fund two Phase‑2 autoimmune drugs
Palo Alto‑based Evommune filed for an initial public offering to fund late‑stage development of two oral or biologic candidates for chronic spontaneous urticaria and atopic dermatitis. The...
Mammoth to trial triglyceride‑lowering gene edit — primate data released
Mammoth Biosciences disclosed first monkey data for its lead in vivo gene editing program aimed at permanently lowering triglycerides, and announced plans for an initial clinical trial. The...
Tempus wins $60.5M ARPA‑H contract — AI diagnostics for precision cancer program
Tempus was awarded a $60.5 million, five‑year contract by ARPA‑H to provide testing and CRO services for the ADAPT precision cancer therapy program. Under the agreement, Tempus will deploy its...
Novo buys Akero: $4.7B bet on FGF21 MASH drug
Novo Nordisk agreed to acquire Akero Therapeutics in a cash deal that pays roughly $4.7 billion up front, with contingent payments that could bring the total to about $5.2 billion. The transaction...
Bristol Myers to buy Orbital for $1.5B — stakes in in vivo CAR‑T
Bristol Myers Squibb agreed to acquire Orbital Therapeutics for $1.5 billion in cash, the company announced, marking a strategic move into in vivo CAR‑T platforms. Orbital is developing in vivo...
FDA approves Jascayd: new oral IPF option for rare lung disease
The U.S. Food and Drug Administration granted approval to Jascayd (nerandomilast), a preferential PDE4B inhibitor developed by Boehringer Ingelheim, for idiopathic pulmonary fibrosis (IPF). The...
Intellia reports in vivo gene‑editing gains — HAE and ATTR progress
Intellia Therapeutics presented clinical updates on its in vivo gene‑editing programs at ESGCT, reporting durable pharmacodynamic effects and safety signals across multiple trials. The company...